Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Original Submission
4 Jan 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
3 Feb 2021 Reviewed Reviewer Report
15 May 2021 Reviewed Reviewer Report - Ryo Morita
8 Jun 2021 Author responded Author comments - Jaclyn Beca
Resubmission - Version 3
8 Jun 2021 Submitted Manuscript version 3
9 Jun 2021 Author responded Author comments - Jaclyn Beca
Resubmission - Version 4
9 Jun 2021 Submitted Manuscript version 4
14 Jun 2021 Reviewed Reviewer Report
19 Jun 2021 Reviewed Reviewer Report - Ryo Morita
14 Jul 2021 Author responded Author comments - Jaclyn Beca
Resubmission - Version 5
14 Jul 2021 Submitted Manuscript version 5
27 Jul 2021 Author responded Author comments - Jaclyn Beca
Resubmission - Version 6
27 Jul 2021 Submitted Manuscript version 6
16 Aug 2021 Reviewed Reviewer Report - Ryo Morita
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
23 Aug 2021 Editorially accepted
29 Oct 2021 Article published 10.1186/s12885-021-08746-z

You can find further information about peer review here.

Back to article page